NovoCure Limited – NASDAQ:NVCR

Add to watchlist

$12.059

-18.64

-60.72%

Market closed

Open in 2 days

+70.75%

month

+70.75%

quarter

+102.24%

year

Market Cap	3.24B
Enterprise value	7.34B

P/E	-73.57
EV/Sales	13.65
EV/EBITDA	-122.38
Price/Sales	12.78
Price/Book	15.58
PEG ratio	1.28
EPS	-1.8

Revenue	525.65M
EBITDA	-158.63M
Income	-192.74M
Revenue Q/Q	13.35%
Revenue Y/Y	0.60%

Profit margin	-17.2%
Oper. margin	-16.64%
Gross margin	78.64%
EBIT margin	-16.64%
EBITDA margin	-30.18%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

NovoCure Limited Stock Forecast

M Q Y

Last Year

$30

Potential upside: 148.77%

Analysts Price target
Financials & Ratios estimates

NovoCure Limited (NASDAQ:NVCR): Profit margin
Jun 2023	126.05M	-57.41M	-45.55%
Sep 2023	127.32M	-49.48M	-38.87%
Dec 2023	133.78M	-47.07M	-35.19%
Mar 2024	138.50M	-38.76M	-27.98%

NovoCure Limited (NASDAQ:NVCR): Earnings per share (EPS)
2022-10-27	-0.23947	-0.25
2022-12-31	-0.34615	-0.35518
2023-02-23	-0.42491	-0.36

NovoCure Limited (NASDAQ:NVCR): Debt to assets
Jun 2023	1159015000	743.33M	64.13%
Sep 2023	1146353000	752.64M	65.66%
Dec 2023	1146129000	783.63M	68.37%
Mar 2024	1121429000	762.07M	67.96%

NovoCure Limited (NASDAQ:NVCR): Cash Flow
Jun 2023	-22.73M	-13.89M	7.50M
Sep 2023	-19.31M	17.25M	1.17M
Dec 2023	-14.55M	98.5M	1.91M
Mar 2024	-31.57M	246.21M	213K

NovoCure Limited alternative data

NovoCure Limited
Employees

NovoCure Limited (NASDAQ:NVCR): Employee count
Aug 2023	1,320
Sep 2023	1,320
Oct 2023	1,320
Nov 2023	1,320
Dec 2023	1,320
Jan 2024	1,320
Feb 2024	1,320
Mar 2024	1,453
Apr 2024	1,453
May 2024	1,453
Jun 2024	1,453
Jul 2024	1,453

NovoCure Limited
Hedge Funds Holdings Q2 2022

76.46% -1.05%

of NVCR is owned by hedge funds

298 +9

hedge funds hold NVCR stock

79.65M -856.4K

shares is hold by hedge funds

NVCR hedge funds holdings changes

NovoCure Limited
Insider Trading

NovoCure Limited (NASDAQ:NVCR): Insider trades (number of shares)
Period	Buy	Sel
Aug 2023	0	1144
Sep 2023	0	1450
Nov 2023	0	382
Feb 2024	0	4381
Mar 2024	0	5843
Jun 2024	0	2892

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	5 Jun 2024	GROENHUYSEN WILHELMUS CM officer: Chief Op..	Ordinary Shares	124,373	$22.82	$2,838,192
Option	5 Jun 2024	GROENHUYSEN WILHELMUS CM officer: Chief Op..	Stock Options (Right to buy)	124,373	$7.15	$889,267
Sale	4 Jun 2024	VERNON W ANTHONY director director	Ordinary Shares	964	$23.89	$23,033
Sale	4 Jun 2024	SCANNELL TIMOTHY J director	Ordinary Shares	964	$23.89	$23,027
Sale	4 Jun 2024	LEUNG GABRIEL director director	Ordinary Shares	964	$23.89	$23,025
Sale	4 Mar 2024	GROENHUYSEN WILHELMUS CM officer: Chief Op..	Ordinary Shares	1,217	$16.01	$19,484
Sale	4 Mar 2024	LEONARD FRANK X officer: EVP, Pres., Novocure Oncology officer: EVP, Pres., Novocure O..	Ordinary Shares	840	$16.01	$13,448
Sale	1 Mar 2024	GROENHUYSEN WILHELMUS CM officer: Chief Op..	Ordinary Shares	2,107	$16.03	$33,769
Sale	1 Mar 2024	LEONARD FRANK X officer: EVP, Pres., Novocure Oncology officer: EVP, Pres., Novocure O..	Ordinary Shares	1,679	$16.03	$26,909
Sale	28 Feb 2024	LEONARD FRANK X officer: EVP, Pres., Novocure Oncology officer: EVP, Pres., Novocure O..	Ordinary Shares	2,078	$16.14	$33,545

NVCR insider trading transactions

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Treating tumors with TTFields and an aurora kinase inhibitor Filling date: 8 Apr 2019 Issue date: 12 Apr 2022	8 Apr 2019	12 Apr 2022
Grant	Grant Utility: Delivering tumor treating fields (TTFields) to the infratentorial brain Filling date: 4 Sep 2018 Issue date: 2 Nov 2021	4 Sep 2018	2 Nov 2021
Grant	Grant Utility: Treating patients with TTFields with the electrode positions optimized using deformable templates Filling date: 13 Dec 2017 Issue date: 7 Sep 2021	13 Dec 2017	7 Sep 2021
Grant	Grant Utility: Temperature measurement in arrays for delivering TTFields Filling date: 11 Aug 2017 Issue date: 24 Aug 2021	11 Aug 2017	24 Aug 2021
Grant	Grant Utility: TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements Filling date: 17 Dec 2018 Issue date: 25 May 2021	17 Dec 2018	25 May 2021
Grant	Grant Utility: Reducing motility of cancer cells using tumor treating fields (TTFields) Filling date: 3 Apr 2017 Issue date: 3 Nov 2020	3 Apr 2017	3 Nov 2020
Grant	Grant Utility: Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment Filling date: 21 Apr 2017 Issue date: 22 Sep 2020	21 Apr 2017	22 Sep 2020
Application	Application Delivering Tumor Treating Fields (TTFields) to the Infratentorial Brain Filling date: 4 Sep 2018 Issue date: 5 Mar 2020	4 Sep 2018	5 Mar 2020
Grant	Grant Utility: Arrays for longitudinal delivery of TTFields to a body Filling date: 29 Jun 2017 Issue date: 15 Oct 2019	29 Jun 2017	15 Oct 2019
Application	Application TTField Treatment with Optimization of Electrode Positions Based on Low Frequency (<1MHZ) AC Conductivity Estimates Derived From Two MRI Images Having Different Repetition Times Filling date: 9 Apr 2019 Issue date: 10 Oct 2019	9 Apr 2019	10 Oct 2019

NovoCure Limited
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 2 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 22 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 26 Oct 2023	Q3 2023 Earnings Call Transcript
Q2 2023 27 Jul 2023	Q2 2023 Earnings Call Transcript

NVCR earnings call transcripts

NovoCure Limited
Executives

Insider	Age	Compensation
Mr. Asaf Danziger (1966) Pres, Chief Executive Officer & Director	59	$2,010,000
Mr. William F. Doyle (1962) Executive Chairman	63	$1,830,000
Mr. Wilhelmus C. M. Groenhuysen (1958) Chief Operating Officer	67	$1,440,000
Mr. Todd C. Longsworth (1975) Gen. Counsel	50	$1,150,000
Ms. Ashley Cordova (1979) Chief Financial Officer & Vice President of Investor Relations	46	$995,200
Mr. Pritesh Shah (1978) Chief Commercial Officer	47	$946,170

NovoCure Limited
Latest News

Friday, 6 December 2024
08:32	Why NovoCure Stock Was Winning Big This Week	fool.com
Thursday, 5 December 2024
04:29	Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?	fool.com
Wednesday, 4 December 2024
21:59	NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer	seekingalpha.com
Tuesday, 3 December 2024
11:01	NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals	zacks.com
Monday, 2 December 2024
13:10	Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields	seekingalpha.com
10:12	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients	benzinga.com
08:57	Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds	investors.com
07:17	Novocure's pancreatic cancer treatment meets main goal in late-stage study	reuters.com
07:02	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer	businesswire.com
07:00	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer	businesswire.com
Wednesday, 27 November 2024
07:00	Novocure to Participate in Upcoming Investor Conferences	businesswire.com
Thursday, 21 November 2024
07:05	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma	businesswire.com
07:00	FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma	businesswire.com
Wednesday, 30 October 2024
11:53	NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript	seekingalpha.com
09:16	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
07:02	Novocure Appoints Christoph Brackmann as Chief Financial Officer	businesswire.com
07:00	Novocure Reports Third Quarter 2024 Financial Results	businesswire.com
Wednesday, 16 October 2024
11:00	NovoCure: There Is Still More Upside	seekingalpha.com
07:28	FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients	benzinga.com
04:45	NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?	zacks.com
Tuesday, 15 October 2024
16:43	FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer	businesswire.com
Tuesday, 1 October 2024
07:00	Novocure to Report Third Quarter 2024 Financial Results	businesswire.com
Monday, 9 September 2024
07:00	Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy	businesswire.com
Friday, 6 September 2024
17:19	Why NovoCure Stock Dived by 13% This Week	fool.com
Friday, 16 August 2024
11:01	Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet	zacks.com
Thursday, 1 August 2024
08:21	New Strong Buy Stocks for August 1st	zacks.com
Tuesday, 30 July 2024
10:56	Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade	zacks.com
Friday, 26 July 2024
12:34	NovoCure Limited: A Post Q2 Analysis	seekingalpha.com
Thursday, 25 July 2024
12:35	NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript	seekingalpha.com
09:10	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates	zacks.com

Ideas & Opinions

Seeking Alpha 30 Jul 2025

NovoCure's Wearable Oncology Edge And Compelling Valuation
Seeking Alpha 24 May 2025

NovoCure: Loading Up On Growth Catalysts
Seeking Alpha 25 Apr 2024

These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Seeking Alpha 17 Nov 2023

NovoCure: Significant Upside Even Without A Breakthrough
Seeking Alpha 23 Aug 2023

NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum
Seeking Alpha 25 Jul 2023

NovoCure At 5 Year Lows: Avoid Or Opportunity?
Seeking Alpha 27 Mar 2023

NovoCure: Pipeline Conversion Is Key
Seeking Alpha 20 Mar 2023

Exploring The Potential Of NovoCure's TTFields In Non-Small Cell Lung Cancer
Seeking Alpha 7 Feb 2023

NovoCure: Ramifications Of Recent Management Change
Seeking Alpha 9 Jan 2023

NovoCure: Catalysts Stacking For More Upside

Frequently Asked Questions (FAQ)

What's the price of NovoCure Limited stock today?

One share of NovoCure Limited stock can currently be purchased for approximately $12.06.
When is NovoCure Limited's next earnings date?

Unfortunately, NovoCure Limited's (NVCR) next earnings date is currently unknown.
Does NovoCure Limited pay dividends?

No, NovoCure Limited does not pay dividends.
How much money does NovoCure Limited make?

NovoCure Limited has a market capitalization of 3.24B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 5.3% to 509.34M US dollars. NovoCure Limited made a loss 207.04M US dollars in net income (profit) last year or -$0.36 on an earnings per share basis.
What is NovoCure Limited's stock symbol?

NovoCure Limited is traded on the NASDAQ under the ticker symbol "NVCR".
What is NovoCure Limited's primary industry?

Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
How do i buy shares of NovoCure Limited?

Shares of NovoCure Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are NovoCure Limited's key executives?
NovoCure Limited's management team includes the following people:
- Mr. Asaf Danziger Pres, Chief Executive Officer & Director(age: 59, pay: $2,010,000)
- Mr. William F. Doyle Executive Chairman(age: 63, pay: $1,830,000)
- Mr. Wilhelmus C. M. Groenhuysen Chief Operating Officer(age: 67, pay: $1,440,000)
- Mr. Todd C. Longsworth Gen. Counsel(age: 50, pay: $1,150,000)
- Ms. Ashley Cordova Chief Financial Officer & Vice President of Investor Relations(age: 46, pay: $995,200)
- Mr. Pritesh Shah Chief Commercial Officer(age: 47, pay: $946,170)
How many employees does NovoCure Limited have?

As Jul 2024, NovoCure Limited employs 1,453 workers.
When NovoCure Limited went public?

NovoCure Limited is publicly traded company for more then 9 years since IPO on 1 Oct 2015.
What is NovoCure Limited's official website?

The official website for NovoCure Limited is novocure.com.
How can i contact NovoCure Limited?

NovoCure Limited can be reached via phone at +44 1534 756700.
What is NovoCure Limited stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for NovoCure Limited in the last 12 months, the avarage price target is $30. The average price target represents a 148.77% change from the last price of $12.06.

NovoCure Limited

novocure.com

Exchange:

NASDAQ

Full time employees:

1,453

Industry:

Medical - Instruments & Supplies

Sector:

Healthcare

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

+44 1534 756700

No. 4 The Forum
Saint Helier, JE2 4UF

CIK: 0001645113
ISIN: JE00BYSS4X48
CUSIP: G6674U108